Although MRI is the workhorse of brain tumor initial evaluation and follow-up, there is a growing amount of data recommending the incorporation of amino-acid PET imaging at different stages of the management of these patients. Recent nuclear medicine and neuro-oncology clinical practice recommendations support the use of amino-acid imaging in brain tumor imaging. Considering 18F-DOPA is FDA approved for the evaluation of parkinsonian syndromes, it could be used clinically for other valuable clinical indications such as brain tumor evaluations. This value seems to be well established in adults and has growing evidence for its use in pediatrics as well. We offer to present four pediatric brain tumor cases imaged with 18F-DOPA and review the literature.
Keywords: Correlative Imaging; MRI; Molecular Imaging; Oncology: Brain; PET; PET/CT; PET/MRI; Pediatrics; Radiation Therapy Planning; amino acid imaging; brain tumors; nuclear medicine.
Copyright © 2022 by the Society of Nuclear Medicine and Molecular Imaging, Inc.